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Risk of the development of multiple sclerosis (MS) is known to be increased in
individuals bearing distinct class II human leukocyte antigen (HLA) variants, whereas
some of them may have a protective effect. Here we analyzed distribution of a highly
polymorphous HLA-DRB1 locus in more than one thousand relapsing-remitting MS
patients and healthy individuals of Russian ethnicity. Carriage of HLA-DRB1∗15 and
HLA-DRB1∗03 alleles was associated with MS risk, whereas carriage of HLA-DRB1∗01
and HLA-DRB1∗11 was found to be protective. Analysis of genotypes revealed the
compensatory effect of risk and resistance alleles in trans. We have identified previously
unknown MBP153−161 peptide located at the C-terminus of MBP protein and MBP90−98
peptide that bound to recombinant HLA-DRB1∗01:01 protein with affinity comparable
to that of classical antigenic peptide 306-318 from the hemagglutinin (HA) of the
influenza virus demonstrating the ability of HLA-DRB1∗01:01 to present newly identified
MBP153−161 and MBP90−98 peptides. Measurements of kinetic parameters of MBP and
HA peptides binding to HLA-DRB1∗01:01 catalyzed by HLA-DM revealed a significantly
lower rate of CLIP exchange for MBP153−161 and MBP90−98 peptides as opposed to
HA peptide. Analysis of the binding of chimeric MBP-HA peptides demonstrated that
the observed difference between MBP153−161, MBP90−98, and HA peptide epitopes is
caused by the lack of anchor residues in the C-terminal part of theMBP peptides resulting
in a moderate occupation of P6/7 and P9 pockets of HLA-DRB1∗01:01 by MBP153−161
and MBP90−98 peptides in contrast to HA308−316 peptide. This leads to the P1 and
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P4 docking failure and rapid peptide dissociation and release of empty HLA-DM–HLA-DR
complex. We would like to propose that protective properties of the HLA-DRB1∗01
allele could be directly linked to the ability of HLA-DRB1∗01:01 to kinetically discriminate
between antigenic exogenous peptides and endogenous MBP derived peptides.
Keywords: myelin basic protein, multiple sclerosis, human leukocyte antigen, protective allele, epitope library,
hemagglutinin, genetic predisposition to disease
INTRODUCTION
Human leukocyte antigen (HLA) genes encode proteins that are
capable to bind and present antigenic peptides and, therefore,
play a critical role in the immune responses against pathogens
as well as those resulting in autoimmunity (1–4). Binding
of antigenic peptides to HLA class II molecules produces
binary peptide-HLA ligands displayed on the cell surface for
recognition by T-cell receptors (5). Initially, nascent HLA
proteins are protected by the invariant chain (6). In the endosome
compartment, the invariant chain is partially degraded leaving
HLA class II-associated Ii peptide (CLIP) in the binding groove
(7, 8). Peptide antigens that are processed in the endosomes
could then exchange with CLIP bound to the HLA molecules,
a process that is facilitated by HLA-DM protein (9, 10). Finally,
the peptide-HLA II complex is translocated to the surface of
the antigen presenting cell (APC) for survey by T cells. While
mechanisms of peptide presentation by HLA class II proteins
is well-understood (11, 12), how generation and presentation of
self-peptide-HLA class II ligands results in the development of
autoimmune reactions is still unclear and remains a subject of
a great interest. Indeed, identification of self-peptide-HLA class
II ligands that are linked to autoimmune reactions promises
to provide a clue for understanding of the pathogenesis of
autoimmune disorders (13–15).
Multiple sclerosis (MS), a chronic autoimmune disease of
the central nervous system (CNS), which is characterized by
inflammation, demyelination, and neurodegeneration (16). The
nature of genetic susceptibility to MS is complex and depends
on the interplay between multiple genetic, epigenetic, and
environmental factors (17). Since the early 2000s, genome-wide
association studies have been exploited as a powerful tool for
investigating the genetic basis of MS and have revealedmore than
200 disease-associated loci; however, genes within HLA region
are thought to exert a major genetic contribution to MS risk
(18). Particular alleles of the highly polymorphous HLA class II
DRB1 gene appear to be the strongest genetic determinant for
MS and may influence both predisposition and resistance to the
disease (19). Genetic heterogeneity in MS patients were observed
in different populations. For instance, the HLA-DRB1∗15:01
allele and its associated haplotype (DQB1∗06:02, DQA1∗01:02,
DRB1∗15:0, DRB5∗01:01) have been known as a near-universal
MS risk factor since the 1970s. Analysis of the HLA associations
in Northern European MS populations uncovered many other
HLA-DRB1 alleles (DRB1∗03, ∗01, ∗10, ∗11, ∗14, ∗08) that were
either positively or negatively associated with the disease (20).
The distinct autoantigenic peptides presented by predisposing
alleles have been identified. For instance, DRB1∗15:01 binds
peptide from myelin basic protein (MBP), i.e., MBP85−99
peptide (14), whileDRB5∗01:01 presents MBP86−105 peptide (13)
and DRB1∗04:01 can display MBP111−129 peptide (21). While
these findings define disease-associated peptide-HLA ligands
recognizable by T-cells (21–23), the mechanism providing
resistance to MS by protective HLA alleles is not known. Here,
on a representative cohort of ethnically Russian MS patients
and healthy individuals, we show that group of alleles HLA-
DRB1∗01 is associated with resistance to MS. We have identified
a novel MBP-derived peptide ligand presented by a particular
HLA-DRB1∗01:01 protein and have shown, that this HLA class II
protein can kinetically discriminate between the MBP and virus
peptides suggesting amechanism responsible for resistance toMS
of individuals that carry HLA-DRB1∗01 alleles.
MATERIALS AND METHODS
Patients and Controls
Five hundred and sixty five unrelated relapsing-remitting MS
(hereinafter referred to as “MS”) patients from Moscow Multiple
Sclerosis Center diagnosed according to the McDonald Criteria
(24) and self-reported as Russians were selected for the study.
Four hundred and seventy-one healthy individuals without
neurological disorders and familial history of MS were included
in the control group; they were also self-reported as Russians.
All MS patients and healthy individuals lived in the Moscow
region. Demographic and clinical data for all participants are
presented in Table 1. No significant differences in demographic
characteristics (age and sex ratio) were observed between two
groups. This study was carried out in accordance with the
TABLE 1 | Demographic and clinical data for relapsing-remitting multiple sclerosis





Sex ratio (female/male) 2.3:1
(395/170)
1.9:1 (310/161)
Age (years), mean ± SD 38.8 ± 10.6 44.2 ± 16.4
Individuals with familial history of MS (%) 27 (4.8%) 0
Age at onset (years), mean ± SD 27.4 ± 9.2 –
Disease duration (years), mean ± SD 11.4 ± 7.4 –
EDSS, mean ± SD 2.8 ± 1.2 –
MSSS, mean ± SD 3.4 ± 1.9 –
EDSS, Expanded Disability Status Scale; MSSS, Multiple Sclerosis Severity Score; SD,
Standard Deviation; RRMS, Relapsing-Remitting Multiple Sclerosis.
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recommendations of local ethics committee of the Moscow
Multiple Sclerosis Center. All subjects gave written informed
consent in accordance with the Declaration of Helsinki. The
protocol #13 from 15 September 2014 was approved by the local
ethics committee of the Moscow Multiple Sclerosis Center.
Genotyping and Statistical Analysis
Genomic DNA was extracted from the peripheral blood
samples with QIAamp DNA Blood Midi Kits (QIAGEN). Low-
resolution (two-digital) genotyping of the HLA-DRB1 locus was
performed using HLA-DRB1 real-time PCR Genotyping Kit
(DNA-Technology). HLA-DRB1 alleles and genotypes associated
with risk of MS were identified using the APSampler software
[http://apsampler.sourceforge.net/] and validated with Fisher’s
exact test included in the software. Association was considered
nominally significant; if uncorrected p-values (pf ) for identified
alleles/genotypes were <0.05 and 95% confidence interval (CI)
for odds ratio (OR) did not cross 1. A standard permutation test
with 100 APSampler runs was performed for each finding as a
multiple hypothesis testing correction. The significance threshold
was set at pperm <0.05.
Preparation of Human Dendritic Cells and
Identification of Bound Peptides
The fraction of mononuclear cells (PBMC), containing dendritic
cells (DC) progenitors, were isolated from human blood
according standard protocol (25). 20–50ml of blood from each
donor was diluted 3 times with PBS-EDTA (PBS with 2mM
EDTA), carefully underlayered with 1/4 of volume with Ficoll
solution (1.077 g/cm3, Paneco) and centrifuged at 750 g for
30min at room temperature. The dense band of PBMCs was
removed carefully, placed into 50ml tube, diluted 3 times with
PBS-EDTA, centrifuged at 200 g for 10min at 4◦C and the cell
pellet was once washed with PBS-EDTA. Then it was solved in
RPMI advanced medium with 10% bovine fetal serum, glutamax
and antibiotic-antimicotic (ThermoFisher Scientific), seeded in
25 cm2 cultural flasks in 6∗106 cell/ml concentration. After 2 h
the unbound cells were removed and media was changed to
fresh portion with DC growth factors—IL4 (100 ng/ml) and
GM-CSF (50 ng/ml) (StemCells) and then cultivated for 6 days
with a change of 1/2 of media volume each second day as
described Markov et al. (26). After 6 days full media volume
was changed to fresh portion with Bacterial LipoPolysaccharide
(10 mkg/ml) and cultivated for 24 h for DC maturation. After
7 days DC were unbound by cell scrapper, lysed in PBS with
0.25% of sodium deoxycholate in presence of complete EDTA-
free inhibitors (Roche), PMSF, Pepstatin, EDTA for 1 h at 4◦C
with following centrifugation at 16,000 g for 20min. Then cell
lysates were applied onto size-exclusion chromatography column
Superdex75 (GE Healthcare). Presence of MHC II molecules
in several high-molecular fractions, corresponding to MHCII
tetramers, were verified by ELISA, where MHCII molecules
were defined by binding with pre-immobilized mouse L243
antibody (anti-MHCII) and following successive interaction
with rabbit anti-MHCII polyclonal serum and with anti-rabbit
anti-whole molecule antibody-HRP (Sigma). These fractions
were lyophilized.
LC-MS/MS and DATA Analysis
Isolated peptides were desalted using SDB-RPS StageTips as it
was described earlier (27). LC-MS/MS analysis was performed
using the Q Exactive HF benchtop Orbitrap mass spectrometer
(Thermo Fisher Scientific) which was coupled to the Ultimate
3000 Nano LC System (Thermo Fisher Scientific) via a
nanoelectrospray source (Thermo Fisher Scientific). The HPLC
system was configured in a trap-elute mode. Peptide solution
were loaded on an Acclaim PepMap 100 (100µm × 2 cm) trap
column and separated on an Acclaim PepMap 100 (75µm ×
50 cm) column (both fromThermo Fisher Scientific). Correlation
of MS/MS spectra with peptide sequences was made using
PEAKS Studio 8.0 build 20160908 software (28). Peptide lists
generated by the PEAKS Studio were searched against the Homo
sapiens Uniprot FASTA database (154257 species, version July
2016) and with methionine oxidations and asparagine/glutamine
deamidations as variable modifications. The false discovery
rate (FDR) for peptide-spectrum matches was set to 0.01
and was determined by searching a reverse database. Peptide
identification was performed with an allowed initial precursor
mass deviation up to 10 ppm and an allowed fragment mass
deviation of 0.05 Da.
MHC Expression and Purification
The genetic constructions for recombinant HLA-DR (HLA-
DRB1∗01:01 and HLA-DRB1∗15:01) α and β (with or without
CLIP) chains expression were created based on pMT-V5/His
and pRmHa vectors, respectively. All HLA-DRs carried parts
of leucine zipper from c-jun and c-fos transcription factors as
previously described (29). CLIP (PVSKMRMATPLLMQA) was
covalently attached with the linker with a thrombin site at the
N-terminus of β chain. The individual stable lines of Drosophila
melanogaster S2 cells, carrying both genes of appropriate α
and β (with or without CLIP) HLA-DR chains and separate
plasmid pCoBlast (Invitrogen) with blasticidin resistance, were
obtained. The HLA-DRB1 proteins with and without CLIP were
expressed in SF900 III Media (Gibco) during 3–7 days after
induction with 1mM Cu2+ at 28◦C with shaking. Then the
cell culture concentrate was applied to affinity anti-MHC II
(L243) resin in PBS, followed by elution with 50mM glycine
buffer (pH 11.5) and rapid neutralization of eluate by 2M
Tris-HCl (pH 8.0) (29). For the next step, impurities were
removed with MonoQ column (GE Healthcare) in 0–1M NaCl
gradient. Constructions for recombinant HLA-DM α and β
chain expression in eukaryotic suspension cells, HEK 293F, were
previously created based on pFUSE vector encoding constant
fragments of human immunoglobulin heavy chain (Fc) (29).
The appropriate constructions were used for transit transfection
of HEK293F cells with a following expression of HLA-DM,
performed in serum-free FreeStyle medium (Gibco) until the
percentage of living cells was lower than 60% (typically 5–
7 days). Then the concentrated culture medium was loaded
into a Protein G affinity column (GE Healthcare), followed
by elution with 50mM glycine buffer (pH 2.5) and rapid
neutralization of eluate by 2M Tris-HCl (pH 8.0). The second
purification step comprised the use of an ion-exchange MonoQ
column (GE Healthcare), following the same procedure as
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described above. Proteins were concentrated, transferred to




Thioredoxin-fused peptides were constructed and produced
earlier as parts of an MBP epitope library (30). Twelve
successive overlapping short fragments of MBP (25–30 aa)
were placed on the C-terminus of bacterial thioredoxin via
flexible linker (SGGGG)3S, carrying an His-tag for purification.
The substrate construct, carrying only thioredoxin with the
linker (TRX), was used as a control. New thioredoxin-fused
peptides were created in this work, using MBP epitope library
as a template. The genetic constructs, encoding HA, pp65,
CLIP, MBP with point mutations and chimeric peptides, were
obtained by insertion using overlapping PCR. All thioredoxin-
fused substrates were produced in Escherichia coli BL21 (DE3)
strain in soluble form, purified with Ni-NTA (Qiagen) and
MonoS (GE Healthcare) columns (30). Thioredoxin-fused
peptides were chemically biotinylated with EZ-Link Sulfo-NHS-
LC-biotin (Thermo Fisher Scientific) in molar ratio 1:20 for
30min at 25◦C. Proteins were concentrated in PBS and stored
at−20◦C.
Peptide Binding Experiments and
Dissociation Constant Determination
Both biotinylated synthetic and thioredoxin-fused MBP peptides
(750 nM, which is much higher than measured KD to study
maximal binding) from the MBP library and with point
mutations, were incubated overnight at 37◦C in PBS in 50
µl with HLA-DR (HLA-DRB1∗01:01 or HLA-DRB1∗15:01)
(150 nM). DR/peptide complexes were then captured on the
ELISA plate with immobilized L243 mAb (5µg/ml in PBS)
and blocked with 1% milk in PBS. HLA-DR-bound biotinylated
peptide was quantitated with streptavidin-peroxidase (50 µl in
PBST), using 3,3′,5,5′-tetramethylbenzidine (50 µl) as a substrate
and stopping with 10% phosphoric acid (50 µl). ELISA was
performed using standard protocol (https://www.abcam.com/
protocols/sandwich-elisa-protocol).
In a competition assay, biotinylated thioredoxin-fused HA
and pp65 peptides (150 nM) were incubated with HLA-DR in the
presence of HA, pp65,MBP or chimeric peptides (1,000, 500, 250,
125, 62.5, 31.2, 15.6, and 7.8 nM) for 18 h. Whole procedure was
the same as described above.
For KD determination, biotinylated synthetic and
thioredoxin-fused peptides were incubated in the same
conditions as described above with HLA-DR (5 nM) at the
following concentrations: 10,000, 3,000, 1,000, 300, 100, 30,
10, 3, and 0.1 nM. DR/peptide complexes were quantitated
using Europium-labeled streptavidin and enhancement solution.
DELFIA was performed according to standard protocol (http://
www.perkinelmer.com/lab-products-and-services/application-
support-knowledgebase/delfia/delfia-immunoassays.html). All
experiments were carried out in triplicates.
Kinetic Measurement of Peptide Loading
on HLA-DR
A real-time ELISA assay was used to assess kinetics of peptide
exchange on HLA-DR, catalyzed by HLA-DM. The linker
connecting the CLIP peptide to the N-terminus of the HLA-
DR β chain was cut with thrombin (1 h, 20 U/mg, at room
temperature). DR-CLIP complexes (150 nM) were incubated
with or without HLA-DM (150 nM, which was estimated as
minimal concentration for maximal rate, see Figure S1) in the
presence of biotinylated either synthetic or thioredoxin-fused
HA, pp65, MBP, and chimeric peptides (150 nM, which was
experimentally estimated as minimal concentration required for
reliable detection), for 7, 5, 3, 1, and 0 h. Each time point was
mixed separately starting from the end of incubation time (7 h)
every 2 h, afterwards all time points were loaded into the plate.
In a competition assay, kinetic experiments were carried out
as described above. Kinetics were measured in the presence
of increasing concentrations (0, 30, 100, 300, and 1,000 nM)
of thioredoxin-fused HA, pp65, MBP, or chimeric peptides at
timepoints 8, 6, 4, 2, and 0 h. Thioredoxin without any peptide
was used as a control. ELISA was performed as done previously.
All experiments were carried out in triplicates.
RESULTS
Genetic Association of HLA-DRB1 Gene
Variants With MS
We analyzed HLA-DRB1 allelic distribution in 565MS patients
and 471 healthy individuals (all of Russian ethnicity) using
low-resolution (two-digital) genotyping. Significant differences
in carriage frequencies of several HLA-DRB1 groups of alleles
(hereinafter “alleles”) were observed (Figure 1A and Table S1).
Alleles HLA-DRB1∗03 and ∗15 were strongly associated with
high MS risk [pperm = 0.0056, OR = 1.77 (CI: 1.27–2.49) and
pperm = 5.8 × 10
−14, OR = 2.84 (CI: 2.17–3.72), respectively].
HLA-DRB1∗01, ∗09, ∗11, and ∗12 alleles were significantly
enriched in the control group. However, only alleles HLA-
DRB1∗01 and ∗11 were determined to be protective after
correction for multiple comparisons [pperm = 0.00062, OR
= 0.55 (CI: 0.41–0.74) and pperm = 0.0011, OR = 0.56
(CI: 0.42–0.76), respectively], while others simply remained
nominally significant.
We further analyzed frequencies of heterozygous genotypes
including one risk allele (HLA-DRB1∗03 or ∗15) and one
resistance allele (HLA-DRB1∗01 or ∗11), i.e., ∗01/∗15, ∗11/∗15,
∗01/∗03, and ∗11/∗03 in MS patients and healthy individuals.
Neither of those genotypes were associated with MS: 95% CI
for OR crossing 1 (Figures 1B–E), while pf -values lay within
the interval between 0.25 and 0.51 (not shown). These data
suggest the compensatory effect of any identified protective and
predisposal alleles in trans. Moreover, dose allele effect was
observed when homozygotes ∗01/∗01, ∗03/∗03, and ∗15/∗15 were
compared with heterozygotes containing HLA-DRB1∗01, ∗03,
or ∗15 alleles in combination with alleles not associated with
MS (denoted as “X” on Figures 1B–E). For HLA-DRB1∗11 allele
(Figures 1C,E), the dose effect was not observed.
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FIGURE 1 | Genetic association of HLA-DRB1 gene variants with MS. (A) Carriage frequencies of HLA-DRB1 alleles in MS patients and healthy controls. pperm values
for alleles DRB1*01, *03, *11 and *15, significantly associated with MS after correction for multiple comparisons, are presented. (B–E) Forest plots demonstrate odds
ratios (ORs) and their 95% confidential intervals (95%CI) for the HLA-DRB1 genotypes that include identified MS predisposing and protective alleles as homozygotes
and in heterozygous combinations with each other or with the rest of the HLA-DRB1 alleles. (B) HLA-DRB1*01 and *15 alleles; (C) HLA-DRB1*11 and *15 alleles; (D)
HLA-DRB1*01 and *03 alleles; (E) HLA-DRB1*11 and *03 alleles. For each plot (B–E), a set of all the DRB1 alleles excluding the alleles of interest is denoted by the
letter “X”; OR [95%CI] values are shown in red for positive association with MS genotypes, in green for negatively associated genotypes and in black for
non-significant genotypes.
Genetic constructs bearing HLA-DRB1∗01:01 and ∗15:01
alleles were used for further analyses since these alleles are the
most frequent among corresponding groups of alleles.
HLA-DRB1∗01:01 Binds Encephalitogenic
and C-Terminal Peptides of the Myelin
Basic Protein
We further determined if recombinant HLA-DRB1∗01:01,
encoded by the most common allele among HLA-DRB1∗01
groups [http://allelefrequencies.net/hla6006a.asp], may bind
MBP-derived peptides utilizing a previously created MBP
epitope library (30) (Figure 2A). HLA-DRB1∗01:01 specifically
bound MBP146−170 and less efficiently bound three other
peptides MBP130−156, MBP81−104, and MBP65−92 (Figure 2B).
As anticipated, HLA-DRB1∗15:01 specifically recognized
encephalitogenic peptide MBP81−104 (Figure 2B). Two more
fragments, namely MBP25−54 and MBP130−156, were bound
by HLA-DRB1∗15:01; however, with significantly diminished
efficiency. Obtained data were verified utilizing chemically
synthesized biotinylated peptides (Figure 2C). The HLA-
DRB1∗01:01 recognized its classical ligand–immunodominant
peptide 306-318 of the hemagglutinin (HA) of the influenza
virus (31), and both myelin peptides, MBP81−104 and
MBP146−170. The HLA-DRB1
∗15:01 bound only MBP81−104,
and neither HLA-DRB1∗01:01 nor HLA-DRB1∗15:01 bound
irrelevant MBP17−41 peptide. LC-MS/MS analysis of peptides
associated with HLA exposed on the dendritic cells isolated
from normal individual with heterozygous genotype HLA-
DRB1∗01:01/∗15:01 revealed three main MBP regions, which
corresponded to MBP81−104, MBP25−54, and MBP130−156,
that were shown to be bound by HLA-DRB1∗15:01. At
the same time, we failed to detect any peptides related to
MBP146−170, bound by HLA-DRB1
∗01:01 (Figure 2A). In
line with these findings peptide MBP146−170 did not activate
proliferation of CD4-positive T cells according to the CFSE
assay (Figure S2).
Myelin Peptides Recognized by
HLA-DRB1∗01:01 Contained Polar
Residues in P6/P7 and P9
Next, it was important to determine binding epitopes recognized
by HLA-DRB1∗01:01, which are present in MBP81−104 and
MBP146−170. Alanine scanning (substitutions of hydrophobic
and aromatic residues) of the thioredoxin-fused MBP146−170
peptide (Figure 2D) revealed that the P1 pocket in the HLA-
DRB1∗01:01 carrying MBP146−170 is occupied by isoleucine at
position 153 (human MBP1−170 nomenclature). Polar arginine
and serine at positions 159 and 161 represent the P6/P7 and P9
residues, respectively. Alanine scanning of the thioredoxin-fused
MBP81−104 peptide (Figure 2E) resulted in the determination of
the phenylalanine at position 90 as a hydrophobic P1 anchor;
in turn, this suggested that P6/P7 and P9 pockets in the HLA-
DRB1∗01:01 bound with MBP81−104 are occupied by threonine,
proline, and threonine at positions 95, 96, and 98, respectively.
Loading of the HLA-DRB1∗01:01 by Viral
and Myelin Peptides Is Thermodynamically
but Not Kinetically Equal
Dissociation constant (KD) of the HLA-peptide complex may
characterize strength, which is required to remove a fully
docked peptide from the HLA binding groove. To determine
this, we measured KD for the complexes of the HLA-
DRB1∗01:01 with myelin peptides MBP81−104, MBP146−170,
and viral HA306−318. For this purpose, we utilized both
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FIGURE 2 | The HLA-DRB1*01:01 recognizes encephalitogenic and C-terminal parts of the myelin basic protein. (A) Amino acid sequence of the MBP. Overlapping
peptides of the epitope library are indicated. Two epitopes of the HLA-DRB1*01:01 are marked by green and blue. Brackets correspond to the sequences of peptides
associated with HLA exposed on the dendritic cells isolated from normal individual with heterozygous genotype HLA-DRB1*01:01/*15:01 according to LC-MS/MS
analysis. (B) Analysis of binding of HLA-DRB1*15:01 (gray bars) and HLA-DRB1*01:01 (white bars) (150 nM) with the MBP epitope library (750 nM). Trx denotes
thioredoxin. Standard deviation is indicated. (C) Recognition of the chemically synthesized peptides representing MBP fragments and HA306−318 peptide (750 nM) by
the HLA-DRB1*15:01 (gray bars) and HLA-DRB1*01:01 (white bars) (150 nM). Black bars represent background signal (PBS). Standard deviation is indicated. (D,E)
Binding of the thioredoxin-fused peptides and its variants (750 nM) with alanine point substitutions representing MBP146−170 (D) and MBP81−104 (E) with
HLA-DRB1*01:01 (150 nM). Open bars represent background signal. Standard deviation is indicated. Point mutations are indicated by different overtones.
chemically synthesized peptides (Figure 3A) and thioredoxin-
fused recombinant epitopes (Figure 3B). Calculated values of
the KD revealed that HLA-DRB1
∗01:01 binds all epitopes with
approximately similar efficacy (Figure 3C).
Removing the CLIP and docking of the antigenic peptides
on the HLA class II is a dynamic process that is catalyzed
by the HLA-DM (32, 33). During this process, despite similar
affinity, the HA peptide exchanged CLIP loaded onto HLA-
DRB1∗01:01 significantly more rapidly in comparison with
MBP peptides 81-104 and 146-170, whereas HLA-DRB1∗15:01
bound MBP81−104 to a similar rate of the HLA-DRB1
∗01:01–HA
interaction (Figure 3D). Study of loading of these peptides as a
part of thioredoxin fusion proteins on HLA resulted in identical
results (Figure 3E).
C-Terminal P6/P7 and P9 Residues in Viral
and Self-Peptides Make Their Kinetic
Discrimination by HLA-DRB1∗01:01
Possible
To determine the reason for the slow rate of C-terminal myelin
peptide loading on HLA-DRB1∗01:01, we created chimeric
peptides representing combinations of N- and C-terminal
parts of HA306−318, CLIP103−117, MBP151−164, and MBP88−100
(Figures 4A,B). Thioredoxin-fused chimeric peptides bearing
the C-terminal part from the HA peptide (Trx-[HA], Trx-
[MBP151−156-HA], Trx-[MBP88−93-HA], and Trx-[CLIP-HA])
were loaded onHLA-DRB1∗01:01 with or withoutHLA-DMwith
a similar rate regardless of the N-terminal part. Conversely, none
of the chimeric peptides assembled from the C-terminal part
of MBP151−164 or MBP88−100 peptides (Trx-[MBP151−164], Trx-
[HA-MBP157−164], Trx-[CLIP-MBP157−164], Trx-[MBP88−100],
Trx-[HA-MBP94−100]) were capable of efficiently binding HLA-
DRB1∗01:01. Similar to these findings, substitution of the N-
terminal part of the CLIP by fragments from either HA or
MBP151−164 (Trx-[HA-CLIP]and Trx-[MBP151−156-CLIP]) had
only a moderate effect on the HLA-DRB1∗01:01 binding.
In order to elucidate if there is a similar dependence on the
peptide C-terminus in case of HLA-DRB1∗15:01 and MBP85−97,
we created chimeric peptide representing fusion of N-terminal
part of pp65109−123 [antigenic peptide from cytomegalovirus
structural protein (34) and C-terminal part of MBP85−97
(Figure 4C). All peptides (Trx-[pp65], Trx-[pp65-MBP91−97],
and Trx-[MBP85−97]) were loaded on HLA-DRB1
∗15:01 with or
without HLA-DM with a similarly high rate.
C-Terminal Part of Myelin Peptide
Significantly Restricts Its Ability to
Compete With HA Peptide in Terms of
Loading on HLA-DRB1∗01:01
We next determined the ability of MBP151−164 to compete
with HA306−318 for HLA-DRB1
∗01:01 binding. To determine
this, HLA-DRB1∗01:01 was incubated with HLA-DM and
biotinylated thioredoxin-fused HA306−318 (Trx-[HA]bio)
in the presence of increasing concentrations of either Trx-
HA306−318 (Trx-[HA]), Trx-MBP151−164 (Trx-[MBP151−164])
or their chimeric variants (Figure 5A). We determined
that Trx-[MBP151−164] and Trx-[HA-MBP157−164] failed to
compete with Trx-[HA]bio up to a concentration of 1µM,
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FIGURE 3 | HLA-DRB1*01:01 kinetically discriminates peptides with similar thermodynamic affinities. Binding of chemically synthesized peptides HA306−318 (red
curve), MBP81−104 (green curve) and MBP146−170 (blue curve) (A) and their thioredoxin-fused analogous (B) in different concentrations (0.1 nM−3µM) with
HLA-DRB1*01:01 (5 nM) measured by DELFIA with time-resolved fluorescence detection. AU denotes arbitrary units and Trx represents thioredoxin. Dissociation
constants are summarized in (C). Kinetics of binding of chemically synthesized peptides (D) and their recombinant analogous as thioredoxin fusions (E) containing
HA306−318 (red curve), MBP81−104 (green curve), and MBP146−170 (blue curve) (150 nM), to preloaded with CLIP HLA-DRB1*01:01 and HLA-DRB1*15:01 (150 nM) with
(solid curves) or without (dashed curves) HLA-DM (150 nM).
whereas non-biotinylated Trx-[HA] and Trx-[MBP151−156-
HA] decreased binding of Trx-[HA]bio starting from a
concentration of 30 nM. To verify that observed difference is
caused by inappropriate P6/P7 and P9 residues in MBP151−164
peptide, as was shown in case of kinetic discrimination
of myelin and viral peptides, we determined the affinity
of two chimeric peptides Trx-[HA-MBP157−164] and Trx-
[MBP151−156-HA] (Figure 5B) in comparison with their
ability to compete with Trx-[HA]bio for HLA-DRB1∗01:01
binding (Figure 5C). Our data suggest that the comparable
thermodynamically inhibition capacity of Trx-[HA-MBP157−164]
is up to two orders of magnitude lower than Trx-[HA]
and Trx-[MBP151−156-HA].
We also determined the ability of MBP85−97 to compete with
pp65109−123 for HLA-DRB1
∗15:01 binding. To determine this,
HLA-DRB1∗15:01 was incubated withHLA-DMand biotinylated
thioredoxin-fused pp65109−123 (Trx-[pp65]bio) in the presence
of increasing concentrations of either Trx-pp65109−123 (Trx-
[pp65]) or Trx-MBP85−97 (Trx-[MBP85−97]) (Figure 5D). We
showed that Trx-[MBP85−97] is capable to compete with Trx-
[pp65]bio, similar to non-biotinylated Trx-[pp65], decreasing
binding of Trx-[pp65]bio starting from a concentration of
100 nM. Our data suggest that thermodynamic inhibition
capacity of Trx-[MBP85−97] in comparison with Trx-[pp65] and
Trx-[pp65-MBP91−97] is up to half of order of magnitude greater
(Figure 5E).
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FIGURE 4 | Kinetic discrimination of myelin and viral peptides by HLA-DRB1*01:01 is caused by their C-terminal residues. Kinetics of binding of thioredoxin fusions
(150 nM) containing chimeric peptides assembled from N- and C-terminal parts of HA306−318 (red), MBP151−164 (blue), and CLIP (black) with HLA-DRB1*01:01
(150 nM) (A); of HA306−318 (red) and MBP88−100 (blue) with HLA-DRB1*01:01 (150 nM) (B); of pp65109−123 (red) and MBP85−97 (blue) with HLA-DRB1*15:01 (150 nM)
(C) in the presence (solid lines) or absence (dashed lines) of HLA-DM (150 nM) measured by ELISA. Anchor residues are indicated.
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FIGURE 5 | HA peptide prevents loading of MBP146−170 onto the HLA-DRB1*01:01. (A) Recombinant HLA-DRB1*01:01 (150 nM) and HLA-DM (150 nM) were
incubated with biotinylated thioredoxin-fused HA306−318 (Trx-[HA]bio) (150 nM) in the presence of increasing concentrations (0-1µM) of thioredoxin-fused MBP151−164
(Trx-[MBP]), HA306−311-MBP157−164 (Trx-[HA-MBP]), MBP151−156-HA312−318 (Trx-[MBP-HA]) and HA306−318 (Trx-[HA]). Thioredoxin (Trx) without any peptide was used
as a control. At indicated timepoints 8, 6, 4, 2, and 0 h, the amount of bound Trx-[HA]bio was determined by addition of streptavidin-HRP. (B) Binding of thioredoxin
fusions containing HA306−318 (red) and chimeric peptides assembled from N- and C-terminal parts of HA306−318 and MBP151−164 (Trx-[MBP-HA] and Trx-[HA-MBP]) in
different concentrations (3 nM−10µM) with recombinant HLA-DRB1*01:01 (5 nM) measured by DELFIA with time-resolved fluorescence detection. (C) Recombinant
HLA-DRB1*01:01 (150 nM) was incubated with biotinylated thioredoxin-fused HA306−318 (Trx-[HA]bio) (150 nM) in the presence of increasing concentrations (7.8
nM−1µM) of thioredoxin-fused HA306−318 (Trx-[HA]) and chimeric peptides assembled from N- and C-terminal parts of HA306−318 and MBP151−164 (Trx-[MBP-HA] and
Trx-[HA-MBP]). After 18 h of incubation, the amount of bound Trx-[HA]bio was determined by addition of streptavidin-HRP. (D) Recombinant HLA-DRB1*15:01
(150 nM) and HLA-DM (150 nM) were incubated with biotinylated thioredoxin-fused pp65109−123 (Trx-[pp65]bio) (150 nM) in the presence of increasing concentrations
(0-1µM) of thioredoxin-fused MBP85−97 (Trx-[MBP]), pp65109−114-MBP91−97 (Trx-[pp65-MBP]), and pp65109−123 (Trx-[pp65]). Thioredoxin (Trx) without any peptide
was used as a control. At indicated timepoints 5.5, 3.5, 1.5, and 0.5 h, the amount of bound Trx-[pp65]bio was determined by addition of streptavidin-HRP. (E)
Recombinant HLA-DRB1*15:01 (150 nM) was incubated with biotinylated thioredoxin-fused pp65109−123 (Trx-[pp65]bio) (150 nM) in the presence of increasing
concentrations (7.8 nM−1µM) of thioredoxin-fused MBP85−97 (Trx-[MBP]), pp65109−114-MBP91−97 (Trx-[pp65-MBP]), and pp65109−123 (Trx-[pp65]). After 18 h of
incubation, the amount of bound Trx-[pp65]bio was determined by addition of streptavidin-HRP.
DISCUSSION
In the present study, we have shown the strong association of
HLA-DRB1∗15 and ∗03 alleles with MS risk and the significant
protective effect of HLA-DRB1∗01 and ∗11 alleles in ethnic
Russian people. The association between HLA-DRB1∗15 allele
and MS was previously shown based on the analysis of a limited
independent cohort of ethnic Russians (35). For HLA-DRB1∗15,
which is widely known as the strongest genetic risk factor of MS,
we observed that the OR value was equal to 2.84, which is similar
to the results obtained for the majority of European populations
(OR = 3.08) (18). Published data on the association of HLA-
DRB1∗03, ∗01, and ∗11 alleles with MS in different populations
are presented in Table S2. Among 15 studies where these
three alleles were investigated simultaneously (see references in
Table S2), positive association with HLA-DRB1∗03 was observed
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in five studies, negative association with HLA-DRB1∗01 in seven
and with ∗11 only in three reports. Results of the meta-analysis
derived for Caucasians in 2011 revealed the associations of
carriage (phenotype) frequencies of HLA-DRB1∗03 and ∗01, but
not for ∗11 with MS, and OR values for ∗03 and ∗01 alleles were
close to those observed in our study (19). Therefore, our data
suggest that Russians share MS-associated HLA-DRB1 ∗03 and
∗01 alleles with other Caucasians.
The OR values for HLA-DRB1∗15, ∗03, and ∗01 were
markedly higher in people who are homozygous for these
allelic variants in comparison with heterozygotes individuals
containing the same alleles (see Figures 1B, D). These data
revealed a dose-depended effect not only for risk alleles HLA-
DRB1∗15 and ∗03, which was shown earlier (36), but also for
the protective allele HLA-DRB1∗01. For all genotypes containing
one protective and one risk allele, we observed no significant
differences in genotype frequencies between MS patients and
healthy controls. The small number of persons carrying each
of these heterozygous genotypes among patients or healthy
individuals (from 5 to 32 persons) do not allow to reach definitive
conclusions but estimatedOR values close to 1 as well as relatively
narrow CIs suggest the mutual compensation of allelic effects
in heterozygotes. The most prominent compensatory effect was
observed for the genotype HLA-DRB1∗01/∗15 [OR = 0.94 (CI:
0.47–1.91)]. Although the exact mechanisms by which HLA
products encoded by different DRB1 alleles contribute to MS
susceptibility are still unknown, the parameters of autoantigen
binding to HLA proteins may be the key component determining
predisposing or protective effects of HLA allelic variants on
MS development.
We have found that the most abundant HLA-DRB1∗01:01
allelic variant binds C-terminal and encephalitogenic peptide
fragments of MBP with affinity comparable to that of exogenous
viral peptides, such as we considered in this work, or even
endogenous peptides with high affinity and slow dissociation
kinetics (37). Loading of the peptide is mediated by a multistep
mechanism including release of the CLIP, which is facilitated by
the binding of HLA-DM to HLA-DRB1∗01:01; tryptophan 43 of
alpha chain of the HLA-DR protein plays an essential role in the
binding (12) (Figure 6). Further, P6-P9 pockets are occupied by
the C-terminal end of the peptide that facilitates interactions of
the N-terminal “head” of the peptide with the P1 and P4 pockets
followed by the release of the HLA-DM. These data provide
evidence that HLA class II molecules are capable to discriminate
kinetically between self- and exogenous peptides during HLA-
DM-catalyzed CLIP exchange. Importantly, the affinity of the
peptides for the HLA protein are very similar, while the on-
rate of their loading onto the HLA are very different. This
indicates that the binding kinetics of HLA ligands may be more
essential characteristic as opposed to the affinity of the binding
and is more relevant physiologically. It should be emphasized
that nature proposes at least several other mechanisms to avoid
autoimmunity in case of HLAs still capable for self-peptides
loading. Molecular dynamics simulation of HLA-DR2—peptide
interaction in the absence of DM reveled that protective allele
DRB1∗16:01 in contrast to the predisposing allele DRB1∗15:01
forms more stable complex with the self-peptide in comparison
with the viral one. This difference is further reasoned by more
tight interaction of the C-terminal part of the self MBP peptide
with DRB1∗16:01. These data suggest that weak binding of HLA
FIGURE 6 | Molecular mechanism of the kinetic selection mediated by the HLA-DM–HLA-DRB1*01:01 complex, which restricts loading of the autoantigenic peptides.
Release of the CLIP is followed by assembling of the HLA-DM–HLA-DRB1*01:01 complex, where tryptophan 43 of the HLA α chain is trapped by the HLA-DM. Myelin
and exogenous (viral HA as representative example) peptides are competing with each other to bind this bimolecular complex utilizing P6/P7 and P9 residues.
Moderate binding of polar P6/P7 and P9 residues in myelin peptides in contrast to the beneficial hydrophobic anchors in the HA peptide does not provide enough
time for P1 residue to attack a respective pocket for complete docking.
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with mimicking viral peptide in case of presence of high affinity
self-peptide may serve as a protective factor (38, 39). Recent
reports also demonstrate that HLA molecules with high affinity
toward self-antigens and associated with autoimmune protection
may “steal epitopes” (40) or induce self-epitope specific T
regulatory cells (41).
Overall, the data suggest that the binding of MBP153−161
and MBP88−100 epitopes to HLA-DRB1
∗01:01 is inefficient,
particularly at the first stage, because the P7 pocket is occupied
by the basic bulky arginine residue or structurally unfavorable
proline, respectively, instead of the highly hydrophobic leucine
residue. Therefore, a moderate interaction of the peptide with
P6/7 and P9 pockets in contrast to the binding of HA peptide
leads to the P1 and P4 docking failure resulting in the
peptide dissociation and release of the empty HLA-DM-HLA-
DR complex (Figure 6). Because the time for HLA class II
loading in the late endosome is restricted to several hours
(42), low rate of peptide binding becomes more critical than
high affinity of their interactions resulting in the inability to
compete with peptides having fast kinetics and even lower
affinity. For that reason, the HA peptide completely blocks
loading of the myelin peptide onto the HLA-DRB1∗01:01
in the equimolar concentration. Thus, it is unlikely that
myelin-derived peptides will be presented in the context of
the HLA-DRB1∗01:01 on the cell surface of the antigen
presenting cells at sufficient density required to initiate T
cell response. It appears that protective properties of the
HLA-DRB1∗01 allele may be directly linked to the ability of
HLA-DRB1∗01:01 to kinetically discriminate between myelin
and exogenous peptides. From the opposite side, risk allele
HLA-DRB1∗15:01 is capable to rapidly present myelin-derived
peptides even in competition with exogenous peptides, such as
viral pp65109−123. Ex vivo analysis of HLA-associated peptidome
from heterozygous HLA-DRB1∗01/∗15-positive dendritic cells
revealed presence of MBP fragments related to the HLA-
DRB1∗15 but not to HLA-DRB1∗01. Even so the observed
compensatory effect of protective HLA-DRB1∗01 and MS-
predisposing ∗15 alleles that are co-dominantly expressed in
heterozygotes may be explained by dispersion of MBP-loaded
HLA-DRB1∗15 complexes by HLA-DRB1∗01 molecules within
MHC clusters, occurring in the immunological synapses formed
between T cells and antigen presenting cells (43). Indeed,
the density of functional MHC molecules within membrane
clusters has proved to be an essential factor regulating T cell
responses (44).
MS therapeutic glatiramer acetate (GA) or Copaxone is a 40–
100 amino acids polypeptide of a random sequence composed
from alanine, lysine, glutamate, and tyrosine at a molar ratio of
4.5:3.6:1.5:1, respectively, that with high affinity binds directly
to the purified HLA-DR1, -DR2, and -DR4 molecules (45).
Combinatorial chemistry, which lays in the basis of GA, may
result in assembling of multiple HLA class II epitopes, that at
least in part may be not simply thermodynamically but rather
kinetically preferable. Concluding our data provide novel vector
of optimization of altered peptide ligands in terms of kinetic
discrimination of HLA class II antigens.
Future studies should determine if the proposed molecular
mechanism of antigenic peptide loading to MHC II suggesting
the kinetic discrimination step may have a more general
significance in protecting humans from autoimmunity along
with the central tolerance established during negative thymic
selection of developing T cells.
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